Hepatitis B Vaccine (Recombinant)

Vir Biotechnology presents Phase 2 SOLSTICE trial data on tobevibart and elebsiran for chronic hepatitis delta and B at AASLD's The Liver Meeting® in San Diego, November 15-19, 2024.

Vir Biotechnology to present Phase 2 SOLSTICE trial data on tobevibart and elebsiran for chronic hepatitis delta at AASLD's The Liver Meeting, highlighting efficacy, safety, and economic burden.

A trial at West China Hospital recruits HBV patients with HBsAg+, HBeAg-, HBeAb+, normal ALT, detectable HBV DNA, no cirrhosis, and treatment-naïve. Treatment group receives antiviral drugs (ETV, TDF, TAF, TMF) for 96 weeks; control group gets regular assessments. Primary outcomes: virological response, HBV pgRNA levels, quality of life. Secondary outcomes: HBsAg loss, liver fibrosis scores, liver nodules, cirrhosis, HCC. Sample size: 300 (150 per group). Randomization stratified by HBV DNA levels. Data collected by CRCs, managed securely. Adherence promoted through reminders and consultations.

Barinthus Biotherapeutics has completed enrolment for its vaccine trials in chronic hepatitis B (CHB) and prostate cancer. The Phase IIb HBV003 trial is evaluating VTP-300 in 121 adults with CHB, while the Phase I PCA001 trial is testing VTP-850 in 22 men with rising prostate-specific antigen (PSA). Both trials aim to determine dosing regimens and evaluate safety and efficacy. Data readouts are expected in Q4 2024 and H1 2025, respectively.

Barinthus Biotherapeutics completes enrollment for HBV003 and PCA001 trials, evaluating VTP-300 for chronic Hepatitis B and VTP-850 for prostate cancer. Interim data for HBV003 expected in Q4 2024, and for PCA001 in H1 2025.

Barinthus Bio completes enrollment for HBV003 and PCA001 trials, with interim data for HBV003 expected in Q4 2024 and PCA001 in H1 2025.

Various cancer vaccines (HPV, Hepatitis B, Her2/neu, MUC1, PSA-TRICOM, TroVax) and emerging treatments (immunotherapy, gene editing, nanotechnology) offer hope. South African health practitioners should embrace innovation, including traditional medicine. Policymakers must support modern treatment regimes and training beyond state institutions. With continued innovation, cancer can be eliminated within 3-5 years.

HEPLISAV-B should not be administered to individuals with severe allergic reactions to its components or previous hepatitis B vaccines. Immunocompromised individuals may have a diminished response. The vaccine may not prevent infection if administered during an unrecognized infection. Common adverse reactions include injection site pain, fatigue, and headache. There is insufficient data on its use in pregnant women and effects on breastfeeding. Vaccination may not protect all recipients. HEPLISAV-B does not treat liver diseases and not all liver cancer is caused by hepatitis B.